Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Mesoblast

Mesoblast

A regenerative medicine company developing biologic products for inflammatory ailments, cardiovascular disease and back pain

Mesoblast has an intellectual property portfolio of more than 1000 patents or patent applications including the use of mesenchymal stem cells/mesenchymal stromal cells (MSCs) for treatment of patients with acute respiratory distress syndrome (ARDS), inflammatory lung disease due to COVID-19, influenza and other viruses.

Their MSC product called Remestemcel-L is being testing in clinical trials for inflammatory conditions including elderly patients with lung disease and adults and children with steroid-refractory acute graft-vs.-host disease (aGVHD). Mesoblast’s stem cell therapy is under review by the FDA for treatment of children with steroid-refractory aGVHD. Remestemcel-L is being developed for rare pediatric and adult inflammatory conditions. The product is comprised of culture-expanded MSCs derived from bone marrow of an unrelated donor (allogeneic) that is administered in a series of intravenous infusions. The therapy is thought to have immunomodulatory properties which counteract inflammatory processes including down-regulation of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines and enabling recruitment of anti-inflammatory cells already in the body to the diseased tissue. Remestemcel-L is previously known under the product name Prochymal by the company Osiris Therapeutics. In 2013 Mesoblast acquired Prochymal and Osiris’ culture-expanded mesenchymal stem cell business.

As of March 2020, Mesoblast has plans to evaluate its allogeneic mesenchymal stem cell (MSC) candidate, remestemcel-L in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 in the US, Australia, China and Europe. ARDS is the and immune system overreaction to the virus in the lungs that causes severe damage to lung tissue. Allogeneic MSCs have been reported to cure or significantly improve functional outcomes of seven treated patients with severe COVID-19 pneumonia in a clinical study in China. Remestercel-L infusions have been tested on patients with chronic obstructive pulmonary disease (COPD) shown to be well tolerated, reduce inflammatory biomarkers and improve pulmonary function in patients with elevated inflammatory biomarkers. The same inflammatory markers are elevated in patients with ARDS due to COVID-19.

Timeline

November 11, 2020
Mesoblast Limited announces randomized controlled Phase 3 trial of remestemcel-L in patients with moderate to severe acute respiratory distress syndrome (ARDS).
2001
Mesoblast was founded by Silviu Itescu.

Patents

Further Resources

Title
Author
Link
Type
Date

Phase 3 Trial of Mesoblast's Cell Therapy in Chronic Heart Failure Completes Recruitment

Mesoblast Limited

Web

News

Title
Author
Date
Publisher
Description
Kyle LaHucik
September 1, 2021
FierceBiotech
Mesoblast has been put on blast by the FDA yet again after the agency requested another trial for its failed, Novartis-backed COVID-19 respiratory treatment. The Australian cell therapy biotech will have to conduct another study of remestemcel-L to have a shot at an emergency use authorization from the FDA.
BioSpace
May 25, 2021
BioSpace
Mesoblast Limited announced that the peer-reviewed journal Respiratory Research has published results showing that Mesoblast's mesenchymal stromal cell product candidate remestemcel-L significantly improved respiratory and functional clinical outcomes in patients with chronic obstructive pulmonary disease and elevated levels of the inflammatory biomarker C-reactive protein.
Ben Adams
March 15, 2021
FierceBiotech
Novartis is kick-starting a new trial with Molecular Partners for an experimental COVID-19 drug just a few months after another partnered attempt flopped.
Phil Taylor
December 18, 2020
FierceBiotech
Australian biotech Mesoblast has been riding high on expectations for its COVID-19 treatment, licensed to Novartis, but fell back to Earth after it said a phase 3 trial of the cell therapy was a bust.
Pomerantz LLP
December 5, 2020
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO) and...
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.